Multiprofile Hospital For Active Treatment-Uni Hospital Ltd. — Clinical Trial Site

39 Registered trials

17 Currently recruiting

Organisation

Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.

Location

Panagyurishte, Bulgaria

Identifier

ORG-100045081

Address

Georgi Benkovski Street 100, 4500, Bulgaria

Departments

Cardiology Clinic
Clinic of cardiology
Department - Medical Oncology Level III
Department – Medical Oncology Level III
Department of Cardiology
Department of internal diseases
Department of Medical Oncology
Medical oncology department
Medical Oncology Deptartment
N/A
Neurology Clinic
Oncology
Oncology Department

Clinical trials at this site (39)

Search interface

DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Pending

2025-520565-51-00 small cell lung cancer 5
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Large cell neuroendocrine carcinoma 4 2023-10-17
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Non-Small Cell Lung Cancer 5 2025-05-14
MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting

2023-507776-42-00 Non-small cell lung cancer 5 2024-11-14
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended

2024-515538-34-00 Head and Neck Squamous Cell Carcinoma 10 2025-02-27
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17